PetMed Express, Inc.
PETS- 1M
- -25.0%
PetMed Express, Inc. in brief
PetMed Express, Inc. is a listed company in the Retail - Pharmacy industry, based in Delray Beach, Florida, USA. It was founded in 1996. Its market value was $27 M on 15 October 2026, which makes it the 23,451st largest listed company in the world and the 4,068th largest in the USA on this site. In the year to March 2026 it had sales of $179 M and a net loss of $57 M. It employs about 212 people and Jeffrey Allen Willard is its chief executive. Its largest business segments by sales in 2026 were Reportable (100%). Its shares trade under the symbol PETS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About PetMed Express, Inc.
PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
PetMed Express, Inc. timeline
- 1996
- 🏁· approximateFounded
- 2000
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- •Legal Entity Identifier issuedLEI 529900PGHW5ASJ1AZL48 registered.
- 2020
- 💰Record revenue of $304 millionFY2020, the highest of the 8 years on record.
Events of PetMed Express, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,518 (Jan 2020) · #2,541 (Jan 2021) · #3,231 (Jan 2022) · #2,911 (Dec 2022) · #3,215 (Jul 2023) · #3,419 (Jan 2024) · #2,115 (Mar 2026) · #3,805 (Aug 2026) · #3,967 (Sep 2026) · #4,071 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.2×
- Price / book
- 0.9×
- Free cash flow yield
- -123.7%
- Net margin (TTM)
- -17.0%
- Operating margin
- -32.8%
- Return on equity
- -94.0%
- Liabilities / assets
- 64.4%
- Revenue growth
- -21.1%
- Revenue per employee
- $844 K
- Profit per employee
- $-270 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $179M | -21.1% | $-59M | $-57M | -32.0% |
| Mar 2025 | $227M | -17.2% | $-2M | $-6M | -2.8% |
| Mar 2024 | $274M | +10.7% | $-8M | $-7M | -2.7% |
| Mar 2023 | $248M | -9.1% | $6M | $5M | 2.1% |
| Mar 2022 | $272M | -10.3% | $24M | $19M | 6.9% |
| Mar 2021 | $304M | +6.8% | $31M | $24M | 7.9% |
| Mar 2020 | $284M | +0.2% | $31M | $26M | 9.1% |
| Mar 2019 | $283M | — | $46M | $38M | 13.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2026 | $-28M | $5M | $-33M | $-2.74 | $0.00 |
| Mar 2025 | $5M | $5M | $-0M | $-0.30 | $0.00 |
| Mar 2024 | $4M | $5M | $-0M | $-0.37 | $0.60 |
| Mar 2023 | $28M | $5M | $23M | $0.25 | $1.20 |
| Mar 2022 | $19M | $2M | $17M | $0.92 | $1.20 |
| Mar 2021 | $40M | $2M | $38M | $1.19 | $1.12 |
| Mar 2020 | $39M | $2M | $37M | $1.29 | $1.08 |
| Mar 2019 | $45M | $1M | $45M | $1.84 | $1.06 |
Quarterly results
Latest quarter to Sep 2026: revenue $36M (-19.4% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Sep 28, 20268-KCurrent reportDirectors or officers changed
- Sep 21, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Sep 17, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 12, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jul 23, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Jun 26, 20268-KCurrent reportDirectors or officers changed
- Jun 25, 2026DEF 14AProxy statement
- Jun 2, 202610-KAnnual report · period to Mar 2026
Official filings of PetMed Express, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $179 M
- Operating income
- $-59 M
- Net income
- $-57 M
For year ending March-2026 · source: SEC filing
Balance sheet
- Total assets
- $81 M
- Total liabilities
- $52 M
- Total equity
- $29 M
As of March-2026
Top 48 institutional investors in PetMed Express, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies LLC | 1,070,630 | -60,600 (-5.36%) | 4.82% | $1 M | Nov 12, 2026 |
| 2 | Vanguard Capital Management LLC | 827,397 | 0 (0.00%) | 3.72% | $1 M | Nov 13, 2026 |
| 3 | BlackRock, Inc. | 467,747 | -100,508 (-17.69%) | 2.10% | $1 M | Nov 13, 2026 |
| 4 | Tudor Investment Corp Et Al | 251,604 | +170,197 (+209.07%) | 1.13% | $0 M | Nov 16, 2026 |
| 5 | UMB Bank, n.a. | 235,000 | +175,000 (+291.67%) | 1.06% | $0 M | Nov 6, 2026 |
| 6 | Steel Partners Holdings L.P. | 193,664 | 0 (0.00%) | 0.87% | $0 M | Nov 10, 2026 |
| 7 | Geode Capital Management, LLC | 175,665 | -28,410 (-13.92%) | 0.79% | $0 M | Nov 6, 2026 |
| 8 | UBS Group AG | 169,196 | +30,866 (+22.31%) | 0.76% | $0 M | Nov 10, 2026 |
| 9 | State Street Corp | 138,273 | +33,100 (+31.47%) | 0.62% | $0 M | Nov 12, 2026 |
| 10 | Bridgeway Capital Management, LLC | 133,541 | +12,493 (+10.32%) | 0.60% | $0 M | Nov 16, 2026 |
| 11 | Federated Hermes, Inc. | 131,196 | -80,974 (-38.16%) | 0.59% | $0 M | Nov 12, 2026 |
| 12 | Price T Rowe Associates Inc /MD/ | 129,933 | 0 (0.00%) | 0.58% | $0 M | Nov 16, 2026 |
| 13 | Vanguard Fiduciary Trust Co | 110,481 | 0 (0.00%) | 0.50% | $0 M | Nov 13, 2026 |
| 14 | Empowered Funds, LLC | 104,841 | +22,493 (+27.31%) | 0.47% | $0 M | Nov 13, 2026 |
| 15 | Formidable Asset Management, LLC | 78,451 | -7,100 (-8.30%) | 0.35% | $0 M | Nov 3, 2026 |
| 16 | Dimensional Fund Advisors LP | 60,353 | 0 (0.00%) | 0.27% | $0 M | Nov 4, 2026 |
| 17 | Rangeley Capital, LLC | 58,855 | -62,145 (-51.36%) | 0.26% | $0 M | Nov 16, 2026 |
| 18 | Citadel Advisors LLC | 55,276 | -18,851 (-25.43%) | 0.25% | $0 M | Nov 16, 2026 |
| 19 | Northern Trust Corp | 40,598 | -2,055 (-4.82%) | 0.18% | $0 M | Nov 16, 2026 |
| 20 | Susquehanna International Group, LLP | 38,603 | -9,130 (-19.13%) | 0.17% | $0 M | Nov 16, 2026 |
| 21 | XTX Topco Ltd | 27,630 | -14,303 (-34.11%) | 0.12% | $0 M | Nov 16, 2026 |
| 22 | IMC-Chicago, LLC | 18,243 | -4,681 (-20.42%) | 0.08% | $0 M | Nov 5, 2026 |
| 23 | Goldman Sachs Group Inc | 12,383 | New | 0.06% | $0 M | Nov 16, 2026 |
| 24 | American Century Companies Inc | 12,266 | -605 (-4.70%) | 0.06% | $0 M | Nov 12, 2026 |
| 25 | Simplex Trading, LLC | 12,122 | -12,723 (-51.21%) | 0.05% | $0 M | Nov 4, 2026 |
Show all 48: investors 26 to 48
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Morgan Stanley | 12,097 | +493 (+4.25%) | 0.05% | $0 M | Nov 13, 2026 |
| 27 | Vanguard Global Advisers, LLC | 8,120 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 28 | Citigroup Inc | 3,450 | +3,441 (+38233.33%) | 0.02% | $0 M | Nov 4, 2026 |
| 29 | Osaic Holdings, Inc. | 2,067 | -1,460 (-41.39%) | 0.01% | $0 M | Nov 12, 2026 |
| 30 | Tower Research Capital LLC (TRC) | 1,372 | +1,204 (+716.67%) | 0.01% | $0 M | Nov 16, 2026 |
| 31 | SBI Securities Co., Ltd. | 985 | -134 (-11.97%) | 0.00% | $0 M | Oct 22, 2026 |
| 32 | Bank & Trust Co | 823 | 0 (0.00%) | 0.00% | $0 M | Oct 7, 2026 |
| 33 | Nuveen, LLC | 633 | New | 0.00% | $0 M | Nov 10, 2026 |
| 34 | Harbour Investments, Inc. | 540 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 35 | Allworth Financial LP | 494 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 36 | Jones Financial Companies Lllp | 415 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 37 | Ascentis Independent Advisors | 356 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
| 38 | Wells Fargo & Company/mn | 300 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 39 | BNP Paribas Financial Markets | 291 | -8,895 (-96.83%) | 0.00% | $0 M | Nov 12, 2026 |
| 40 | Rothschild Investment LLC | 250 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 41 | Farther Finance Advisors, LLC | 151 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 42 | FMR LLC | 104 | +44 (+73.33%) | 0.00% | $0 M | Nov 10, 2026 |
| 43 | Elevated Capital Advisors, LLC | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 44 | Royal Bank Of Canada | 31 | +1 (+3.33%) | 0.00% | $0 M | Nov 16, 2026 |
| 45 | Caitong International Asset Management Co., Ltd | 11 | -1 (-8.33%) | 0.00% | $0 M | Oct 29, 2026 |
| 46 | Barclays PLC | 7 | New | 0.00% | $0 M | Nov 6, 2026 |
| 47 | CoreCap Advisors, LLC | 4 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 48 | Steward Partners Investment Advisory, LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding PetMed Express, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 602,795 | $1 M | 2.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 211,088 | $0 M | 0.95% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 112,623 | $0 M | 0.51% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value FundFederated Hermes Equity Funds | 116,820 | $0 M | 0.53% | 0.13% | no change | Jun 30, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Core ETFFederated Advisory Services Company | 75,863 | $0 M | 0.34% | 0.06% | +56% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 82,722 | $0 M | 0.37% | <0.01% | +2.4% | Jun 30, 2026 |
| 🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers | 82,348 | $0 M | 0.37% | 0.01% | +9.8% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 51,552 | $0 M | 0.23% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Total Equity Market Index FundT. Rowe Price Associates, Inc. | 48,911 | $0 M | 0.22% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 35,726 | $0 M | 0.16% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 38,500 | $0 M | 0.17% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 28,931 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 25,000 | $0 M | 0.11% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 12,060 | $0 M | 0.05% | <0.01% | −48% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 13,514 | $0 M | 0.06% | <0.01% | −19% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 10,000 | $0 M | 0.04% | 0.01% | −66% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 4,946 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 4,410 | $0 M | 0.02% | <0.01% | −86% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,587 | $0 M | 0.02% | <0.01% | +36% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC | 2,303 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 1,442 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation | 1,000 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust | 605 | $0 M | <0.01% | <0.01% | −86% | May 31, 2026 |
| 🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC | 588 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Equity FundAmerican Century ETF Trust | 188 | $0 M | <0.01% | <0.01% | −33% | May 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 117 | $0 M | <0.01% | <0.01% | +6.4% | Jul 31, 2026 |
| 🇺🇸 Avantis Responsible U.S. Equity ETFAmerican Century ETF Trust | 18 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 27 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at PetMed Express, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Douglas KrulikCAO and Interim CFO | Shares withheld for tax | -2,435 | $1.190 | $3 K | 90,608 | Form 4 |
| filed | Jeffrey Allen WillardCEO and President, Director | Grant or award | +250,000 | — | — | 250,000 | Form 4 |
| filed | Douglas KrulikCAO and Interim CFO | Shares withheld for tax | -3,246 | $1.530 | $5 K | 93,043 | Form 4 |
| filed | Tamar ElkelesDirector | Grant or award | +49,923 | — | — | 49,923 | Form 4 |
| filed | Leslie C.g. CampbellInterim CEO and President, Director | Grant or award | +60,000 | — | — | 145,000 | Form 4 |
| filed | James LaCampDirector | Grant or award | +55,555 | — | — | 90,421 | Form 4 |
| filed | Peter BatushanskyDirector | Grant or award | +55,555 | — | — | 91,928 | Form 4 |
| filed | Justin L. MennenDirector | Grant or award | +55,555 | — | — | 98,274 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: PetMed Express, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Dividend, quarter | Per share | |
|---|---|---|
| Q1 2025 | $0.000 | from the annual figure |
| Q4 2024 | $0.000 | |
| Q3 2024 | $0.000 | |
| Q2 2024 | $0.000 | |
| Q1 2024 | $0.000 | from the annual figure |
| Q4 2023 | $0.000 | |
| Q3 2023 | $0.300 | |
| Q2 2023 | $0.300 | |
| Q1 2023 | $0.300 | from the annual figure |
| Q4 2022 | $0.300 | |
| Q3 2022 | $0.300 | |
| Q2 2022 | $0.300 | |
| Q1 2022 | $0.300 | from the annual figure |
| Q4 2021 | $0.300 | |
| Q3 2021 | $0.300 | |
| Q2 2021 | $0.300 | |
| Q1 2021 | $0.280 | from the annual figure |
| Q4 2020 | $0.280 | |
| Q3 2020 | $0.280 | |
| Q2 2020 | $0.280 | |
| Q1 2020 | $0.270 | from the annual figure |
| Q4 2019 | $0.270 | |
| Q3 2019 | $0.270 | |
| Q2 2019 | $0.270 | |
| Q1 2019 | $0.270 | from the annual figure |
| Q4 2018 | $0.270 | |
| Q3 2018 | $0.270 | |
| Q2 2018 | $0.250 | |
| Q1 2018 | $0.250 | from the annual figure |
| Q4 2017 | $0.200 | |
| Q3 2017 | $0.200 | |
| Q2 2017 | $0.200 | |
| Q1 2017 | $0.190 | from the annual figure |
| Q4 2016 | $0.190 | |
| Q3 2016 | $0.190 | |
| Q2 2016 | $0.190 | |
| Q1 2016 | $0.180 | from the annual figure |
| Q4 2015 | $0.180 | |
| Q3 2015 | $0.180 | |
| Q2 2015 | $0.180 |
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2021 | Q4 2021 | $0M |
| Q4 2020 | Q3 2021 | $0M |
| Q3 2020 | Q2 2021 | $0M |
| Q2 2020 | Q1 2021 | $0M |
| Q1 2020 | Q4 2020 | $0M |
| Q4 2019 | Q3 2020 | $0M |
| Q3 2019 | Q2 2020 | $0M |
| Q2 2019 | Q1 2020 | $11.5M |
| Q1 2013 | Q4 2012 | $0M |
| Q4 2012 | Q3 2012 | $0M |
| Q1 2012 | Q4 2011 | $0M |
| Q4 2011 | Q3 2011 | $1M |
| Q3 2011 | Q2 2011 | $9.1M |
| Q2 2011 | Q1 2011 | $13.6M |
| Q1 2011 | Q4 2011 | $7M |
| Q4 2010 | Q3 2011 | $1M |
Trading halts
- 2025-12-16 17:04 UTC, code LUDP, resumed 17:09 UTC
Fails to deliver
- : 2,697 shares at $1.20
- : 1,594 shares at $1.60
- : 3,984 shares at $1.62
- : 3 shares at $1.76
- : 5 shares at $1.98
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
PetMed Express, Inc. scorecard#
Passes 4 of the 24 checks that could be worked out: strongest in valuation (2 of 5), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 15, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.9×Price to book 0.9× against Healthcare's median of 3.1×.
- ✓Price to sales below its peers' median0.2×Price to sales 0.2× against Healthcare's median of 3.8×.
- ✗Free cash flow yield above 5%-123.7%Free cash flow is -123.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 6
- ✗Revenue grew in the newest year-21.1%Revenue down 21.1% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-10.2%-10.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-10.2%-10.2% a year against Retail - Pharmacy's median of 0.4% (6 companies).
- ✗Earnings per share grew in the newest year-2.74 vs -0.30Diluted EPS -2.74 in fiscal 2025 against -0.30 the year before (report's currency).
- ✗Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against $24 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-32.8%-32.8% against Retail - Pharmacy's median of -2.4% (7 companies).
- ✗Return on equity above 15%-100.5%-100.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-32.8%-32.8% in fiscal 2025 against 2.4% in 2022.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.84 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone0.16Z-score 0.16 (distress zone) for fiscal 2025.
Shareholder returns2 of 5
- ✓Pays a dividendYesPaid dividends in fiscal 2025.
- ✗Dividend per share raised five years in a row1 of 5Dividend per share raised in 1 of the five years to fiscal 2025.
- –Dividends under 75% of net incomeNo payout ratio (a loss year).
- ✓Share count up no more than 2% in a year1.6%Diluted shares up 1.6% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.1%Dividends and buybacks were 0.1% of the market value.
- ✗Free cash flow covers dividends and buybacks-$33 MFree cash flow -$33 M against $0 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Retail - Pharmacy, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from PetMed Express, Inc.'s statements, beside the median of Retail - Pharmacy.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -32.8% | -2.4% | |
| Net margin | -32.0% | -1.4% | |
| Return on equity | -100.5% | -49.7% | |
| Revenue growth, 3 years a year | -10.2% | 0.4% | |
| Revenue growth | -21.1% | 8.3% | |
| Free cash flow margin | -18.4% | -0.3% |
2of 8on the Piotroski tests of financial strength
- Revenue fell 21.1% against the year before.
- Net loss of $57 million, the 3th loss-making year in a row.
- Free cash flow was negative: -$33 million.
- Liabilities due within a year exceed current assets (current ratio 0.84).
PetMed Express, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Mar 31, 2026 | FY 2024to Mar 31, 2025 | FY 2023to Mar 31, 2024 | FY 2022to Mar 31, 2023 | FY 2021to Mar 31, 2022 | FY 2020to Mar 31, 2021 | FY 2019to Mar 31, 2020 | FY 2018to Mar 31, 2019 | FY 2017to Mar 31, 2018 | FY 2016to Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 179−21.1%100% | 227−17.2%100% | 274r281+10.7%100% | 248r257−9.1%100% | 272r273−10.3%100% | 304r309+6.8%100% | 284+0.2%100% | 283+3.5%100% | 274+9.9%100% | 249—100% | |
| Cost of revenue | — | 158−16.6%69.5% | 189r202+10.7%69.1% | 171r186−12.4%69.1% | 195−10.9%71.7% | 219+8.1%72.2% | 203+7.9%71.4% | 188+6.9%66.4% | 176+3.6%64.3% | 170—68.2% | |
| Gross profit | 50−27.4%28.1% | 69−18.4%30.5% | 85r79+10.8%30.9% | 77r71−0.6%30.9% | 77r78−8.7%28.3% | 84r90+3.8%27.8% | 81−14.8%28.6% | 95−2.5%33.6% | 98+23.3%35.7% | 79—31.8% | |
| General and administrative | 51+31.3%28.3% | 39−30.0%17.0% | 55+32.4%20.2% | 42r49+34.1%16.8% | 31r31+4.7%11.4% | 30r28+17.6%9.8% | 25+2.0%8.9% | 25+2.0%8.7% | 24+6.5%8.9% | 23—9.1% | |
| Operating expenses | 109+54.1%60.8% | 71−24.0%31.1% | 93r87+31.9%33.9% | 70r72+33.8%28.5% | 53r52−2.1%19.3% | 54r52+7.0%17.7% | 50+2.3%17.7% | 49+7.6%17.3% | 46+9.2%16.7% | 42—16.8% | |
| Operating income | −59—−32.8% | −1.5—−0.7% | −8.2−235%−3.0% | 6.1r−1.4−75.1%2.4% | 24r26−20.4%8.9% | 31r38−1.4%10.1% | 31−32.9%10.9% | 46−11.4%16.3% | 52+39.1%19.0% | 37—15.0% | |
| Interest and finance income | — | — | — | 2.1+518%0.8% | 0.3+6.7%0.1% | 0.3−82.0%0.1% | 1.7−6.3%0.6% | 1.9+183%0.7% | 0.7+367%0.2% | 0.1—0.1% | |
| Other non-operating income (expense) | 1.3+39.3%0.7% | 0.9−50.1%0.4% | 1.9+35.5%0.7% | 1.4r3.0—0.6% | −0.1r1.4−125%−0.0% | 0.4r1.6−85.6%0.1% | 2.9−1.1%1.0% | 2.9+78.3%1.0% | 1.7+275%0.6% | 0.4—0.2% | |
| Income before tax | −57—−32.0% | −0.6—−0.3% | −6.3−184%−2.3% | 7.4r1.6−69.2%3.0% | 24r27−21.9%8.9% | 31r39−8.7%10.2% | 34−31.0%11.9% | 49−8.7%17.3% | 54+41.8%19.6% | 38—15.2% | |
| Income tax | −0.1−101%−0.0% | 5.7+377%2.5% | 1.2−48.3%0.4% | 2.3r1.4−57.9%0.9% | 5.5r6.0−22.2%2.0% | 7.0r8.6−12.6%2.3% | 8.0−29.3%2.8% | 11−31.0%4.0% | 17+17.0%6.0% | 14—5.7% | |
| Net income attributable to shareholders | −57—−32.0% | −6.3—−2.8% | −7.5−245%−2.7% | 5.1r0.2−72.5%2.1% | 19r21−21.8%6.9% | 24r31−7.5%7.9% | 26−31.5%9.1% | 38+1.2%13.3% | 37+56.5%13.6% | 24—9.6% | |
| Earnings per share, basic | -2.74—— | -0.30—— | -0.37−248%— | 0.25r0.01−73.1%— | 0.93r1.05−21.8%— | 1.19r1.53−7.8%— | 1.29−29.9%— | 1.84+0.5%— | 1.83+55.1%— | 1.18—— | |
| Earnings per share, diluted | -2.74—— | -0.30—— | -0.37−248%— | 0.25r0.01−72.8%— | 0.92r1.04−22.7%— | 1.19r1.52−7.8%— | 1.29−29.9%— | 1.84+1.1%— | 1.82+55.6%— | 1.17—— | |
| Shares, weighted average (basic) | 21+1.6%— | 21+1.0%— | 20+0.6%— | 20r20+0.5%— | 20r20+0.6%— | 20+0.1%— | 20−2.1%— | 20+0.6%— | 20+0.6%— | 20—— | |
| Shares, weighted average (diluted) | 21+1.6%— | 21+1.0%— | 20+0.3%— | 20r20−0.1%— | 20r20+1.2%— | 20+0.3%— | 20−2.1%— | 20+0.3%— | 20+0.3%— | 20—— | |
| Dividends per share | 0.00—— | 0.00−100%— | 0.60−50.0%— | 1.200.0%— | 1.20+7.1%— | 1.12+3.7%— | 1.08+1.9%— | 1.06+24.7%— | 0.85+11.8%— | 0.76—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 21−60.9%26.4% | 55−1.0%36.8% | 55−46.9%32.5% | 104−6.3%62.1% | 111−6.4%61.8% | 119+14.4%63.3% | 104+3.2%66.8% | 101+29.0%65.1% | 78+32.7%57.8% | 59—52.1% | |
| Receivables | 1.9−17.7%2.4% | 2.3−29.4%1.6% | 3.3+88.7%1.9% | 1.7−9.0%1.0% | 1.9−26.1%1.1% | 2.6−32.7%1.4% | 3.8+51.2%2.5% | 2.5+10.9%1.6% | 2.3+26.8%1.7% | 1.8—1.6% | |
| Inventory | 14−16.0%16.8% | 16−43.3%10.9% | 29—16.8% | — | — | — | — | — | — | — | |
| Other current assets | 6.4+19.7%7.9% | 5.3−15.7%3.6% | 6.3+34.0%3.7% | 4.7−3.0%2.8% | 4.9+8.1%2.7% | 4.5+27.6%2.4% | 3.5+151%2.3% | 1.4+59.6%0.9% | 0.9−13.4%0.7% | 1.0—0.9% | |
| Current assets | 44−44.8%53.7% | 79−15.8%53.0% | 94−28.2%55.1% | 130r131−13.6%77.9% | 151−6.3%84.0% | 161+24.9%86.0% | 129+2.0%83.1% | 126+20.1%81.9% | 105+28.7%78.0% | 82—72.5% | |
| Property, plant and equipment | 26−8.8%32.4% | 29+8.3%19.4% | 27+1.8%15.7% | 26+7.0%15.6% | 24−3.9%13.6% | 25+0.0%13.6% | 25−6.2%16.4% | 27−5.6%17.6% | 29−4.7%21.3% | 30—26.7% | |
| Right-of-use (leased) assets | 0.5−47.0%0.6% | 1.0−32.5%0.6% | 1.4—0.8% | 0—0.0% | — | — | — | — | — | — | |
| Goodwill | 0−100%0.0% | 270.0%17.9% | 27—15.7% | 0—0.0% | — | — | — | — | — | — | |
| Other intangible assets | 5.5−31.8%6.8% | 8.0−28.2%5.4% | 11+1203%6.6% | 0.9r5.90.0%0.5% | 0.90.0%0.5% | 0.90.0%0.5% | 0.90.0%0.6% | 0.90.0%0.6% | 0.90.0%0.6% | 0.9—0.8% | |
| Investments in associates | — | — | 5.3+6.0%3.1% | 5.0—3.0% | — | — | — | — | — | — | |
| Non-current assets | 38−46.1%46.3% | 70−8.4%47.0% | 76+106%44.9% | 37r33+29.1%22.1% | 29r25+9.1%16.0% | 26+0.0%14.0% | 26−6.0%16.9% | 28−5.4%18.1% | 30−4.6%22.0% | 31—27.5% | |
| Total assets | 81−45.4%100% | 149−12.5%100% | 170+1.4%100% | 167r164−6.8%100% | 180r176−4.2%100% | 187+20.7%100% | 155+0.6%100% | 154+14.5%100% | 135+19.5%100% | 113—100% | |
| Accounts payable | 21−11.3%25.7% | 24−36.4%15.8% | 37+46.9%21.8% | 25−8.3%15.1% | 28−30.5%15.3% | 40+101%21.1% | 20+20.8%12.7% | 16+6.6%10.5% | 15+0.3%11.3% | 15—13.5% | |
| Current liabilities | 52−17.1%64.1% | 63−13.0%42.2% | 72+25.5%42.5% | 58r36+2.2%34.3% | 56r33+25.2%31.3% | 45+84.6%24.0% | 24+30.7%15.7% | 19+2.9%12.1% | 18−1.3%13.4% | 18—16.3% | |
| Lease liabilities (non-current) | 0.0−92.1%0.1% | 0.5−46.2%0.4% | 1.0—0.6% | 0—0.0% | — | — | — | — | — | — | |
| Total liabilities | 52−17.8%64.4% | 64−13.1%42.7% | 73+27.2%43.1% | 58r40+2.2%34.3% | 56r34+21.7%31.3% | 46+82.6%24.6% | 25+28.2%16.3% | 20+3.4%12.8% | 19−1.7%14.2% | 19—17.2% | |
| Retained earnings | 9.3−86.1%11.4% | 67−7.0%44.8% | 72−21.9%42.1% | 92r105−18.0%54.7% | 112r130−16.7%62.2% | 134+6.3%71.5% | 126+3.3%81.2% | 122+14.9%79.1% | 106+22.9%78.9% | 87—76.7% | |
| Shareholders' equity | 29−66.0%35.6% | 85−12.0%57.3% | 97−12.0%56.9% | 110r124−10.9%65.7% | 123r142−1.2%68.7% | 125r141+3.8%66.6% | 120r130−10.6%77.5% | 135+16.4%87.2% | 116+24.0%85.8% | 93—82.8% | |
| Total liabilities and equity | 81−45.4%100% | 149−12.5%100% | 170+1.4%100% | 167r164−6.8%100% | 180r176−4.2%100% | 187+20.7%100% | 155+0.6%100% | 154+14.5%100% | 135+19.5%100% | 113—100% | |
| Shares outstanding | 21+3.5%— | 21−2.3%— | 21r21+0.3%— | 21r21+0.5%— | 21+3.5%— | 20+0.5%— | 20−2.5%— | 21r21+0.4%— | 21+0.4%— | 21—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 9.4+33.4%5.2% | 7.0−0.2%3.1% | 7.1+99.0%2.6% | 3.5+29.5%1.4% | 2.7—1.0% | — | — | — | — | — | |
| Share-based compensation | 1.4—0.8% | −6.6−196%−2.9% | 6.9+3.8%2.5% | 6.6+45.5%2.7% | 4.5+37.6%1.7% | 3.3+17.2%1.1% | 2.8−8.9%1.0% | 3.1+20.3%1.1% | 2.6+33.1%0.9% | 1.9—0.8% | |
| Cash from operating activities | −28−702%−15.9% | 4.7+9.3%2.1% | 4.3−84.5%1.6% | 28+50.3%11.2% | 18−53.8%6.8% | 40+3.2%13.2% | 39−13.9%13.7% | 45+20.8%15.9% | 37−20.8%13.7% | 47—18.9% | |
| Capital expenditure | −4.6—−2.6% | −5.1—−2.3% | −4.5—−1.6% | −5.3—−2.1% | −1.8—−0.6% | −2.4—−0.8% | −2.3—−0.8% | −0.6—−0.2% | −0.7—−0.3% | −11—−4.3% | |
| Acquisitions, net of cash acquired | 0—0.0% | 0—0.0% | −36—−13.1% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Cash from investing activities | −4.6—−2.6% | −5.1—−2.3% | −41—−14.8% | −10—−4.1% | −1.8—−0.6% | −2.4—−0.8% | −2.3—−0.8% | −0.6—−0.2% | −0.7—−0.3% | −11—−4.3% | |
| Shares bought back | — | — | — | — | 0—0.0% | 0—0.0% | −11—−4.0% | 0—0.0% | — | — | |
| Dividends paid | −0.0—−0.0% | −0.2—−0.1% | −12—−4.5% | −25—−9.9% | −24—−9.0% | −23—−7.5% | −22—−7.7% | −22—−7.7% | −17—−6.4% | −16—−6.2% | |
| Cash from financing activities | −0.3—−0.2% | −0.2—−0.1% | −12—−4.5% | −25—−9.9% | −24—−9.0% | −23—−7.5% | −33—−11.7% | −22—−7.7% | −17—−6.4% | −16—−6.2% | |
| Change in cash | −33—−18.6% | −0.6—−0.3% | −49—−17.8% | −7.0—−2.8% | −7.6−151%−2.8% | 15+363%4.9% | 3.2−85.7%1.1% | 23+17.6%8.0% | 19−8.9%7.0% | 21—8.5% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q2 FY2026to Sep 30, 2026 | Q1 FY2026to Jun 30, 2026 | Q4 FY2025to Mar 31, 2026 | Q3 FY2025to Dec 31, 2025 | Q2 FY2025to Sep 30, 2025 | Q1 FY2025to Jun 30, 2025 | Q4 FY2024to Mar 31, 2025 | Q3 FY2024to Dec 31, 2024 | Q2 FY2024to Sep 30, 2024 | Q1 FY2024to Jun 30, 2024 | Q4 FY2023to Mar 31, 2024 | Q3 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 160−19.2%100% | 36−19.4%100% | 41−19.9%100% | 43*−15.6%100% | 41−21.7%100% | 44−23.6%100% | 51−22.7%100% | 51*−22.0%100% | 52r53−18.4%100% | 58r60—100% | 66r68—100% | 65*—100% | 64r65—100% | |
| Cost of revenue | — | 26−18.7%72.6% | 30−19.3%72.4% | — | — | 32−18.6%72.0% | 37−22.0%71.9% | 36*−22.6%70.1% | 36r38−19.0%69.0% | 39r42—67.7% | 47r50—71.2% | 46r48*—70.7% | 44r47—69.5% | |
| Gross profit | 45−23.4%27.8% | 9.8−21.0%27.4% | 11−21.3%27.6% | 14*−8.3%32.6% | 9.5−41.4%23.3% | 12−33.9%28.0% | 14−24.3%28.1% | 15*−20.4%29.9% | 16r15−17.0%31.0% | 19r17—32.3% | 19r18—28.8% | 19r18*—29.3% | 19r18—30.5% | |
| General and administrative | 47−7.2%29.2% | 12−15.6%33.5% | 11−13.5%27.3% | 11*−8.6%26.7% | 12+13.1%30.0% | 14+35.1%32.0% | 13+166%25.3% | 12*−11.7%24.6% | 11−19.7%20.8% | 10r10—18.1% | 4.9—7.4% | 14*—21.7% | 13—21.1% | |
| Operating expenses | 73−31.5%45.8% | 16−22.0%45.4% | 18−63.8%42.8% | 20*−7.5%45.9% | 20+20.2%49.0% | 21+14.1%46.9% | 49+231%94.8% | 21r21*−7.4%41.8% | 17r15−26.3%31.9% | 18r17—31.4% | 15r14—22.1% | 23r22*—35.2% | 22r21—35.3% | |
| Operating income | −29—−18.0% | −6.4—−17.9% | −6.2—−15.2% | −5.7*—−13.3% | −10—−25.7% | −8.4−1613%−18.9% | −34−878%−66.7% | −6.0*—−11.9% | −0.5—−0.9% | 0.6—1.0% | 4.4—6.6% | −3.8*—−5.9% | −3.1—−4.8% | |
| Interest and finance income | — | 0.1−50.0%0.3% | 0.1−66.7%0.2% | — | 0.2−60.0%0.5% | 0.2—0.5% | 0.3—0.6% | — | 0.5—1.0% | — | — | — | — | |
| Interest expense and finance costs | — | 0.2−66.7%0.6% | 0.4−20.0%1.0% | — | 0.40.0%1.0% | 0.6—1.4% | 0.5—1.0% | — | 0.4—0.8% | — | — | — | — | |
| Other non-operating income (expense) | 1.6+1395%1.0% | −0.0—−0.0% | 0.1—0.2% | 1.5*+3924%3.6% | −0.1−135%−0.2% | −0.1−135%−0.3% | −0.0−103%−0.0% | 0.0*−89.3%0.1% | 0.2−51.5%0.4% | 0.4—0.6% | 0.3—0.5% | 0.4*—0.5% | 0.4—0.7% | |
| Income before tax | −27—−17.0% | −6.4—−17.9% | −6.1—−15.0% | −4.2*—−9.7% | −11—−25.9% | −8.5−1020%−19.2% | −34−825%−66.7% | −6.0*—−11.8% | −0.2—−0.5% | 0.9—1.6% | 4.7—7.1% | −3.5*—−5.3% | −2.6—−4.2% | |
| Income tax | −0.1−101%−0.0% | 0.0+55.6%0.0% | 0.0+44.4%0.0% | −0.1*−102%−0.2% | 0.0−97.6%0.0% | 0.0—0.0% | 0.0−99.1%0.0% | 5.7*+269%11.2% | 0.5—0.9% | −1.4—−2.4% | 1.0—1.4% | 1.5*—2.4% | −0.6—−1.0% | |
| Net income attributable to shareholders | −27—−17.0% | −6.4—−18.0% | −6.1—−15.0% | −4.1*—−9.5% | −11—−26.0% | −8.5−466%−19.2% | −34−1010%−66.7% | −12*—−22.9% | −0.7—−1.4% | 2.3—4.0% | 3.8—5.7% | −5.0*—−7.7% | −2.0—−3.2% | |
| Earnings per share, basic | — | -0.31—— | -0.28—— | — | -0.50—— | -0.41−473%— | -1.65−1017%— | — | -0.03—— | 0.11—— | 0.18—— | — | -0.10—— | |
| Earnings per share, diluted | — | -0.31—— | -0.28—— | — | -0.50—— | -0.41−473%— | -1.65−1017%— | — | -0.03—— | 0.11—— | 0.18—— | — | -0.10—— | |
| Shares, weighted average (basic) | 21+0.9%— | 21+0.9%— | 22+4.5%— | — | 21+1.8%— | 21+1.4%— | 21+1.2%— | — | 21+1.0%— | 21—— | 21—— | — | 20—— | |
| Shares, weighted average (diluted) | 21+0.9%— | 21+0.9%— | 22+4.5%— | — | 21+1.8%— | 21−0.2%— | 21−0.9%— | — | 21+1.0%— | 21—— | 21—— | — | 20—— | |
| Dividends per share | — | — | — | — | — | — | — | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 11—19.2% | 11−68.4%19.2% | 13−68.2%20.5% | 21−60.9%26.4% | 27−46.3%30.6% | 36−30.6%36.0% | 41−10.6%37.4% | 55−1.0%36.8% | 50+1.3%34.6% | 52—35.6% | 46—30.1% | 55—32.5% | 49—28.5% | |
| Receivables | 1.4—2.3% | 1.4−30.1%2.3% | 1.7+6.3%2.7% | 1.9−17.7%2.4% | 1.6−31.0%1.8% | 2.0+21.3%2.0% | 1.6−29.0%1.5% | 2.3−29.4%1.6% | 2.3+17.0%1.6% | 1.6—1.1% | 2.3—1.5% | 3.3—1.9% | 1.9—1.1% | |
| Inventory | 6.3—10.6% | 6.3−57.3%10.6% | 8.5−53.9%13.3% | 14−16.0%16.8% | 12+3.5%13.9% | 15+12.8%14.7% | 18—16.7% | 16−43.3%10.9% | 12—8.1% | 13—9.0% | — | 29—16.8% | — | |
| Other current assets | 6.2—10.4% | 6.2−2.7%10.4% | 4.3−34.5%6.7% | 6.4+19.7%7.9% | 7.6+94.7%8.6% | 6.4+74.0%6.3% | 6.5+68.8%5.9% | 5.3−15.7%3.6% | 3.9−55.8%2.7% | 3.7—2.5% | 3.9—2.5% | 6.3—3.7% | 8.8—5.1% | |
| Current assets | 25—42.7% | 25−57.4%42.7% | 28−59.3%43.3% | 44−44.8%53.7% | 49−29.1%55.1% | 59−16.0%59.3% | 68−12.5%61.8% | 79−15.8%53.0% | 68−28.4%47.2% | 71—48.5% | 78—50.8% | 94—55.1% | 96—55.1% | |
| Property, plant and equipment | 23—39.5% | 23−17.2%39.5% | 25−12.6%39.5% | 26−8.8%32.4% | 28−3.1%31.3% | 28+8.1%28.3% | 29+10.4%26.3% | 29+8.3%19.4% | 28+6.0%19.6% | 26—17.9% | 26—17.1% | 27—15.7% | 27—15.5% | |
| Right-of-use (leased) assets | 0.3—0.5% | 0.3−62.5%0.5% | 0.4−53.7%0.6% | 0.5−47.0%0.6% | 0.6−41.8%0.7% | 0.7−37.6%0.7% | 0.9−34.2%0.8% | 1.0−32.5%0.6% | 1.1−33.8%0.7% | 1.2—0.8% | 1.3—0.8% | 1.4—0.8% | 1.6—0.9% | |
| Goodwill | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 270.0%17.9% | 27+0.0%18.4% | 27—18.3% | 27—17.5% | 27—15.7% | 27—15.4% | |
| Other intangible assets | 5.0—8.4% | 5.0−22.5%8.4% | 5.2−24.5%8.2% | 5.5−31.8%6.8% | 6.0−38.6%6.8% | 6.5−36.7%6.4% | 7.0−35.1%6.3% | 8.0−28.2%5.4% | 9.7−16.7%6.7% | 10—7.0% | 11—7.0% | 11—6.6% | 12—6.7% | |
| Investments in associates | — | — | — | — | — | — | — | — | — | — | — | 5.3—3.1% | — | |
| Non-current assets | 34—57.3% | 34−16.6%57.3% | 36−13.8%56.7% | 38−46.1%46.3% | 39−48.4%44.9% | 41−45.7%40.7% | 42−44.1%38.2% | 70−8.4%47.0% | 76−1.8%52.8% | 75—51.5% | 75—49.2% | 76—44.9% | 78—44.9% | |
| Total assets | 59—100% | 59−40.8%100% | 64−41.9%100% | 81−45.4%100% | 88−39.2%100% | 100−31.3%100% | 110−28.1%100% | 149−12.5%100% | 145−16.5%100% | 146—100% | 153—100% | 170—100% | 173—100% | |
| Accounts payable | 15—25.7% | 15−20.2%25.7% | 12−38.6%19.3% | 21−11.3%25.7% | 20+85.5%23.1% | 19+12.8%19.1% | 20−18.1%18.2% | 24−36.4%15.8% | 11−71.8%7.6% | 17—11.6% | 24—16.0% | 37—21.8% | 39—22.4% | |
| Current liabilities | 42—71.3% | 42−25.3%71.3% | 41−29.5%63.7% | 52−17.1%64.1% | 55+14.2%62.3% | 57+16.1%56.5% | 58−1.2%52.5% | 63−13.0%42.2% | 48−33.8%33.1% | 49—33.4% | 58—38.2% | 72—42.5% | 72—41.8% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0.0−92.1%0.1% | 0.2−74.4%0.2% | 0.3−62.1%0.3% | 0.4−53.1%0.4% | 0.5−46.2%0.4% | 0.7−26.7%0.5% | 0.8—0.5% | 0.9—0.6% | 1.0—0.6% | 0.9—0.5% | |
| Total liabilities | 43—71.6% | 43−25.7%71.6% | 41−30.1%63.9% | 52−17.8%64.4% | 55+13.6%62.8% | 57+15.4%57.1% | 58−1.5%53.1% | 64−13.1%42.7% | 49−33.7%33.6% | 50—34.0% | 59—38.8% | 73—43.1% | 73—42.3% | |
| Retained earnings | −3.3—−5.6% | −3.3−114%−5.6% | 3.1−90.4%4.9% | 9.3−86.1%11.4% | 13−83.0%15.1% | 24−69.7%23.8% | 32−57.7%29.5% | 67−7.0%44.8% | 78+2.1%54.0% | 79—54.0% | 77—50.1% | 72—42.1% | 77—44.2% | |
| Shareholders' equity | 17—28.4% | 17−60.8%28.4% | 23−55.4%36.1% | 29−66.0%35.6% | 33−65.9%37.2% | 43−55.3%42.9% | 52−44.9%46.9% | 85−12.0%57.3% | 96−3.9%66.4% | 96—66.0% | 94—61.2% | 97—56.9% | 100—57.7% | |
| Total liabilities and equity | 59—100% | 59−40.8%100% | 64−41.9%100% | 81−45.4%100% | 88−39.2%100% | 100−31.3%100% | 110−28.1%100% | 149−12.5%100% | 145−16.5%100% | 146—100% | 153—100% | 170—100% | 173—100% | |
| Shares outstanding | 22—— | 22+5.3%— | 22+4.1%— | 21+3.5%— | 21+3.5%— | 21+1.7%— | 21+1.1%— | 21−2.3%— | 21−2.4%— | 21—— | 21—— | 21r21—— | 21—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 9.2+11.4%5.7% | 2.2−4.2%6.1% | 2.1−5.9%5.2% | 2.4*+17.0%5.7% | 2.4+51.3%5.9% | 2.3+37.4%5.1% | 2.3+32.7%4.5% | 2.1*+9.4%4.1% | 1.6−10.4%3.1% | 1.7—2.9% | 1.7—2.6% | 1.9*—2.9% | 1.8—2.8% | |
| Share-based compensation | 1.1−41.8%0.7% | 0.3*+63.0%0.9% | 0.2−66.5%0.5% | 0.3*−54.1%0.6% | 0.3−40.0%0.7% | 0.2−66.7%0.5% | 0.6—1.2% | 0.6*−64.6%1.2% | 0.5−70.7%1.0% | 0.6—1.0% | −8.2—−12.4% | 1.7*—2.6% | 1.7*—2.7% | |
| Cash from operating activities | −23—−14.2% | −1.1*—−3.0% | −7.7—−18.7% | −4.7*−168%−11.1% | −9.2*—−22.6% | −2.2*−129%−4.9% | −12—−24.0% | 7.0*−1.6%13.8% | −1.2*—−2.2% | 7.4*—12.7% | −8.5—−12.9% | 7.1*—11.0% | −2.6*—−4.1% | |
| Capital expenditure | — | −0.6*—−1.6% | −0.6—−1.6% | −0.7*—−1.7% | — | −2.6*—−5.9% | −1.3—−2.5% | −2.4*—−4.7% | −0.8*—−1.5% | −1.3*—−2.2% | −0.7—−1.0% | −1.3*—−1.9% | −1.1*—−1.8% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | |
| Cash from investing activities | −1.9—−1.2% | −0.6*—−1.6% | −0.6—−1.6% | −0.7*—−1.7% | 0.0*—0.1% | −2.6*—−5.9% | −1.3—−2.5% | −2.4*—−4.7% | −0.8*—−1.5% | −1.3*—−2.2% | −0.7—−1.0% | −1.3*—−1.9% | −1.4*—−2.2% | |
| Dividends paid | — | 0*—0.0% | 0—0.0% | — | −0.0*—−0.0% | −0.0*—−0.0% | −0.0—−0.0% | −0.0*—−0.0% | −0.0*—−0.0% | −0.1*—−0.1% | −0.1—−0.2% | −0.0*—−0.0% | −0.0*—−0.0% | |
| Cash from financing activities | −0.1—−0.0% | −0.0*—−0.1% | −0.0—−0.0% | −0.0*—−0.1% | 0*—0.0% | −0.2*—−0.5% | −0.0—−0.1% | −0.0*—−0.0% | −0.0*—−0.0% | −0.1*—−0.1% | −0.1—−0.2% | −0.0*—−0.0% | −0.0*—−0.0% | |
| Change in cash | −25—−15.4% | −1.7*—−4.6% | −8.3—−20.3% | −5.5*−219%−12.9% | −9.2*—−22.6% | −5.0*−183%−11.3% | −14—−26.6% | 4.6*−21.1%9.1% | −1.9*—−3.7% | 6.1*—10.4% | −9.3—−14.1% | 5.9*—9.0% | −4.0*—−6.3% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What PetMed Express, Inc. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$179 M100%-21%
Source: SEC annual report (XBRL data) · as of Mar 31, 2026
Executive pay at PetMed Express, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Jeffrey Allen Willard | $830 K | $813 K | $469 K | $9 |
| 2025Jeffrey Allen Willard | $3.9 M | $3.7 M | $666 K | $17 |
| 2024Mr. Mathew N. Hulett | $534 K | −$70 K | $635 K | $20 |
Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026
Events at PetMed Express, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Financial statements withdrawn 1 · Auditor changed 2 · Impairment 1 · Directors and officers 11 · Material agreement 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Auditor changed | 8-K/A | |
| Auditor changed | 8-K | |
| Directors and officersMaterial agreementShareholder rights changed | 8-K | |
| Delisting noticeResults announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Financial statements withdrawnImpairment | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 acquisitions, $36 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| PetCareRx | 2023 | — | $36 M | 100% | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at PetMed Express, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $103 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Software DeveloperSoftware Developers | 1 | $103 K |
Where: Stamford, CT 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as PetMed Express, Inc.
How PetMed Express, Inc. compares in Retail - Pharmacy
- Market cap$27 M · higher than 6% of 35
- Revenue$179 M · higher than 5% of 38
- Net margin-17.0% · higher than 0% of 36
- Revenue growth-21.1% · higher than 10% of 11
- Price / sales0.2× · lower than 96% of 25
- Price / book0.9× · lower than 91% of 23
- FCF yield-123.7% · higher than 0% of 5
Peer comparison · Retail - Pharmacy
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| PetMed Express, Inc.🇺🇸 | $27 M | — | -17.0% | -21.1% |
| Tsuruha Holdings Inc.🇯🇵 | $6.9 B | 23.8× | 2.9% | — |
| Alibaba Health Information Technology Limited🇭🇰 | $6.7 B | 24.0× | 5.7% | — |
| Matsumotokiyoshi Holdings🇯🇵 | $6.2 B | 16.5× | 5.0% | — |
| Yifeng Pharmacy Chain Co., Ltd.🇨🇳 | $4.3 B | 17.8× | 6.9% | — |
| Raia Drogasil S.A.🇧🇷 | $4.1 B | 16.8× | 2.9% | — |
| Selçuk Ecza Deposu Ticaret Ve Sanayi A.S.🇹🇷 | $3.7 B | 72.7× | 3.5% | — |
| Sugi Holdings Co., Ltd.🇯🇵 | $3.3 B | 23.6× | 3.1% | — |
| Cosmos Pharmaceutical Corporation🇯🇵 | $3.3 B | 19.5× | 3.1% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- SFD S.A.$27 M
- 111$32 M
- Arich Enterprise Co., Ltd.$41 M
- MedFirst Healthcare Services, Inc.$64 M
- Sastasundar Ventures Limited$93 M
- LifeMD, Inc.$112 M
Sources and freshness
- Market cap:
- Oct 15, 2026
- Annual results:
- For year ending March-2026
- Balance sheet:
- As of March-2026
- Employees:
- As on 2022
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikimedia Commons, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at PetMed Express, Inc.? Verify and update this profile — free
Show PetMed Express, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.